Cabozantinib is developed and produced by which company?

Cabozantinib (Cabozantinib), sold under the brand names Cometriq and Cabometyx, is an anti-cancer drug. The capsule form is used to treat medullary thyroid cancer, and the tablet form is used to treat renal cell carcinoma, hepatocellular carcinoma and differentiated thyroid cancer. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2 and also inhibits AXL and RET. Cabozantinib was discovered and developed by Exelixis Inc.

In vitro biochemistry and/or cellular assays have shown that cabozantinib inhibits the following receptor tyrosine kinases: MET (hepatocyte growth factor receptor protein) and VEGFR, RET, GAS6 receptor (AXL, KIT) and Fms-like tyrosine kinase-3 (FLT3). These receptor tyrosine kinases are involved in normal cellular functions and pathological processes, such as tumorigenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment. Cabozantinib needs to be taken at about the same time each day. The length of treatment depends on the patient's body's response to the drug and the side effects they experience. Do not take more or less of the drug, or more often than prescribed by your doctor. Cabozantinib tablets and capsules may be swallowed with a full glass (8 ounces, 240 mL) of water. Do not cut, chew, crush or open them.

If a patient experiences severe side effects, doctors may reduce the dose of cabozantinib or permanently or temporarily stop treatment. Cabozantinib has not been tested in pregnant women; it can cause harm to rodent fetuses. Pregnant women should not take this medicine, and women should not become pregnant while taking it. It is unknown whether cabozantinib is excreted in breast milk.